Dr Reddy's Recalls Over 4,000 Bottles Of Drug In US Due To Packaging Error

Dr Reddy's Laboratories is recalling over 4,000 bottles of a generic drug in the US due to a packaging error

Topics

Dr Reddys | United States | Pharamaceutical Industries

Press Trust of India  |  New Delhi 



A large drug firm has 12-15 therapy divisions, and if each launches a few drugs, the company brings to the market 30-50 brands a year.

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

Dr Reddy's Laboratories is recalling over 4,000 bottles of a generic drug in the US due to a packaging error.

The Hyderabad-based drug major is recalling 4,320 bottles of Tacrolimus Capsules which are used to prevent the body from rejecting a transplanted organ.

New Jersey-based Dr Reddy's Laboratories Inc, a unit of the company, is recalling the affected lot due to "Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules," USFDA said in its latest Enforcement Report.

The affected lot was produced at the company's Bachupally-based manufacturing plant and marketed in the US by its American arm.

Dr Reddy's initiated the Class II nationwide recall on February 8 this year.

As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Tue, March 07 2023. 22:54 IST


RECENT NEWS

BoE Loosens Capital Rules

The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more

Monzo Looks For US Banking License

Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more

Crypto Firms Push Into US Banking

America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more

Parallel Banking: Stablecoins Are Now Global

Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more

JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity

JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more

Private Equity And Banks: The Complex Web Of Leverage

Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more